Lan Zhang, Haochen Wu, Shanshan Qi, Lianqi Zhao, Fei Chen, Ying Jin, Juan Zhang, Meng Qiao, Xiaoyu An, Weibin Tan*, Xiaoyan Fu*, Qian Shi, and WenQing Yang
*Taicang Blood Center, Taicang, Suzhou, P.R. China
The recent rise in cancer immunotherapy research and drug approvals is providing promising treatment options for cancer patients, as well as new opportunities for translational scientists to identify and develop new classes of immunomodulatory agent.
This is increasing the demand for complex preclinical models which can be used to fully assess immuno-oncology agents and their many and varied interactions with the immune system, including models for the in vivo assessment of human-specific immunotherapeutics.
CrownBio has developed a platform of PBMC-humanized mouse tumor models, which have a broad spectrum of applications in immuno-oncology including the evaluation of human specific immunomodulatory drugs in vivo. This poster details the characterization and optimization of these models for a range of cancer types.
Your privacy is important to us.
We'll never share your information.
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy
2021-10-28
2021-10-28
landing_page
PDX/Databases